Physician profile
Tobechukwu Clouden
NPI 1669603387
$3,675.73
in general payments reported to CMS, 2019-2025
12 companies · $821 in 2025
The $821 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $95.66 · 2021: $348 · 2022: $504 · 2023: $724 · 2024: $899 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,230.05 |
| Education | $214.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $863.69 | 2020-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $619.91 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $509.36 | 2021-2025 | Vraylar |
| Alkermes, INC. | $424.29 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $422.97 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $258.90 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $189.36 | 2019-2020 | |
| Indivior INC. | $162.87 | 2020-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $101.78 | 2024-2025 | Cobenfy |
| Tempus Ai, INC | $92.45 | 2024 | |
| Vanda Pharmaceuticals INC. | $17.21 | 2025 | Fanapt |
| Lundbeck LLC | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tobechukwu Clouden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.